Salute e Benessere

SciBase receives first order in Austria

"It is pleasing to see that our strategy and belief in Nevisense is beginning to bear fruit. Joachim Kaiser, our sales representative in Austria, does a fantastic job and has managed to get a first sale in a short time. This strengthens our belief that Austria and Switzerland can develop into good markets for us," says Pia Renaudin CEO of SciBase. "It is pleasing to see that our strategy and belief in Nevisense is beginning to bear fruit.Joachim Kaiser, our sales representative…
PR Newswire
30/05/2024

Nanoform's biologics technology showcased by large pharma at drug delivery…

(Numbers in Brackets Refer to the Corresponding Last Year Reporting Period, Unless Otherwise Mentioned.) (Numbers in Brackets Refer to the Corresponding Last Year Reporting Period, Unless Otherwise Mentioned.) * Defined as materials & services expenses, employee benefit expenses, and other operating expenses. ** Including Treasury bills. Part of the cash has been invested in short-term government bonds. ***Cash position after the new share issue wasEUR 54.7 monApril 30, 2024...
PR Newswire
30/05/2024

Cellectis' Annual Shareholders General Meeting to be Held on June 28, 2024

The notice convening the annual general meeting stating the detailed agenda and modalities of participation in the meeting is available on the Cellectis website:https://www.cellectis.com/en/investors/general-meetings/About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of...
Nasdaq GlobeNewswire
29/05/2024

Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences

Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024 Goldman Sachs 45 thAnnual Global Healthcare Conference onWednesday, June 12, 2024 Audio webcasts of the presentations will be available via the Investors section of the Jazz Pharmaceuticals website athttps://investor.jazzpharma.com/investors/events-presentations. A replay of the webcasts will be archived on the website for 30 days. About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (Nasdaq:...
PR Newswire
29/05/2024

GENFIT to Present Latest ACLF Research at EASL Congress™ 2024

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 29, 2024-GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today detailed its presence at the EASL Congress™ 2024. GENFIT accelerates its research in Acute on-Chronic Liver Failure (ACLF)EF CLIF and GENFIT partnership event GENFIT will co-host an event with the European...
Nasdaq GlobeNewswire
29/05/2024

Alkermes to Participate in Two Upcoming Investor Conferences

Goldman Sachs 45th Annual Global Healthcare ConferenceDate/Time:Tuesday, June 11, 2024 at 10:40 a.m. EDT (3:40 p.m. BST) Goldman Sachs 45 thAnnual Global Healthcare Conference Date/Time:Tuesday, June 11, 2024at10:40 a.m. EDT( 3:40 p.m. BST ) The live webcasts may be accessed under the Investors tab onwww.alkermes.comand will be archived for 14 days. About Alkermes plc Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the...
PR Newswire
29/05/2024

Ori Biotech Unveils IRO Platform at Annual International Society for Cell & Gene…

Innovative cell therapy manufacturing platform moving industry toward widespread patient access to life-saving cell and gene therapies Ori Biotech Ltd. (Ori), a leader in cell and gene therapy (CGT) manufacturing technology, announces the commercial launch of IRO ®, a next-generation platform built specifically to overcome the current challenges in CGT manufacturing. The company today revealed the IRO platform at ISCT 2024 , International Society for Cell & Gene Therapy's...
Nasdaq GlobeNewswire
29/05/2024

AB Science provides an update on the application for conditional marketing…

PRESS RELEASEAB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSISParis, 29 May, 2024, 6pm CETAB Science SA(Euronext - FR0010557264 - AB) today announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a trending toward a negative opinion on the application for conditional marketing authorisation of masitinib in the...
Nasdaq GlobeNewswire
29/05/2024

Trading by management and close relations of management

In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B in the attached file.Investor Relations Tobias Bjorklund+45 3077 8682 [email protected] Anders Enevoldsen+45 5350 1453 ...
Nasdaq GlobeNewswire
29/05/2024

CEO "Maxima Grupė" M. Dargužis Will Temporarily Lead "Franmax"

Starting May 30, Manfredas Dargužis, CEO of "MAXIMA GRUPĖ," UAB, will also temporarily lead the subsidiary company FRANMAX, UAB, which handles IT development, support, and maintenance for the group's companies. Karolis Lesickas, who has been leading the company until now, is leaving the group of companies. "We thank Karolis for his work at Franmax and other group companies over the past ten years. K. Lesickas' professionalism has significantly contributed to implementing major IT…
Nasdaq GlobeNewswire
29/05/2024

Sterilization Equipment Market to be Worth $30.71 Billion by 2031 - Exclusive…

Sterilization equipment is an essential measure used across the healthcare industry in order to avoid infectious diseases. Infectious diseases are caused by pathogenic microorganisms, such as bacteria, viruses, parasites, or fungi. The diseases can be spread, directly or indirectly, either from one person to another, from infected or non-sterilized surgical or medical devices used to treat a person, or from being in the infected environment of any healthcare facility. Thus, to prevent and reduce…
PR Newswire
29/05/2024

Clinical Microbiology Market Worth $6.9 billion | MarketsandMarkets™

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=219135367 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=219135367 Browse in-depth TOC on "Clinical Microbiology Market" 67 - Tables 46 - Figures 220 - Pages Clinical Microbiology Market Scope: Instruments segment is expected to register the substantial share by type of products Clinical Microbiology market. The instruments segment...
PR Newswire
29/05/2024

Vaccines Market to Reach $90.7 billion, Globally, by 2035 at 6.4% CAGR: Allied…

Request Sample of the Report on Vaccines Market Forecast 2035 - https://www.alliedmarketresearch.com/request-sample/258 Request Sample of the Report on Vaccines Market Forecast 2035 -https://www.alliedmarketresearch.com/request-sample/258 Prime determinants of growth Increase in prevalence of infectious diseases, surge in immunization programs across the globe, rise in research and development activities, and government funding and regulatory support are the major factors that...
PR Newswire
29/05/2024

High Throughput Screening Market to Be Worth $47.41 Billion by 2031 - Exclusive…

High throughput screening (HTS) is a technique employed in drug discovery to quickly test large numbers of compounds for their potential as therapeutic agents. This methodology is mainly used to screen and analyze millions of compounds in a short period, improving the probability of discovering promising small-molecule drug candidates. High throughput screening (HTS) is a technique employed in drug discovery to quickly test large numbers of compounds for their potential as therapeutic agents...
PR Newswire
29/05/2024

Radiopharmaceuticals Market to Reach $21.8 billion, Globally, by 2033 at 10.6%…

Prime determinants of growth Prime determinants of growth Rise in the prevalence of chronic diseases, rise in the adoption of strategies by key players, and surge in R&D activities within the radiopharmaceuticals sector are the major factors that drive the growth of the global radiopharmaceuticals market. However, the high cost associated with the development and implementation of radiopharmaceuticals restricts the market growth. Moreover, the rise in the number of pipeline products...
PR Newswire
29/05/2024

Dialysis Market to be Worth $36.6 Billion by 2031 - Exclusive Report by…

The growth of the dialysis market is driven by the growing prevalence of kidney disorders, diabetes, and hypertension, the increasing number of dialysis centers, initiatives for chronic kidney care, shortage & side effects of kidney transplant, and the rising prevalence of early-stage renal disease. Additionally, technological advancements in dialysis machines, rising preference for home dialysis, and emerging economies are expected to offer significant market growth opportunities. The…
PR Newswire
29/05/2024

Global Urinary Tract Infection Testing Market to Grow Rapidly at a Growth Rate…

Key Takeaways from the Urinary Tract Infection Testing Market Report Key Takeaways from the Urinary Tract Infection Testing Market Report To read more about the latest highlights related to the urinary tract infection testing market, get a snapshot of the key highlights entailed in theGlobal Urinary Tract Infection Testing Market Report Urinary Tract Infection Testing Overview Urinary tract infection testing plays a pivotal role in diagnosing this common yet uncomfortable condition...
PR Newswire
29/05/2024

SOPHiA GENETICS to Launch New Whole Genome Sequencing Capabilities

The new WGS application from SOPHiA GENETICS will be designed to provide fully analyzed whole genome insights in an accelerated timeline, enabling researchers and clinicians to make data-driven decisions within the same day. This expedited speed will also increase opportunities for researchers and biotechnology companies to innovate rapidly across clinical research, drug discovery and care delivery with improved efficiency and effectiveness. The new WGS application from SOPHiA GENETICS will…
PR Newswire
29/05/2024

Matter Bio Successfully Closes $7M Seed Funding Round

Matter Bio tackles the problem of genome instability holistically, addressing the issue through a multi-pronged approach: Matter Bio tackles the problem of genome instability holistically, addressing the issue through a multi-pronged approach: Matter Bio has assembled a world-class team of scientists and executives, including co-founders such asGeorge Church, PhD, a pioneer in genome sequencing and gene editing, Jan Vijg, PhD, an expert in genome instability and somatic mutations, and...
PR Newswire
29/05/2024

IM Cannabis Closes Convertible Debenture Offering to Support Accelerated Growth…

"Active cost management has been our focus since the beginning of 2023. Last year we concentrated on reducing our operating expenses, reducing our 2023 G&A expenses -49% vs 2022," said Oren Shuster, CEO of IMC. "This year we looked at our financial costs. By renegotiating our debt, we expect a significant reduction in our financing costs. Our goal is to free resources to drive accelerated growth in Germany, where we currently see the biggest potential following the April 1st…
PR Newswire
29/05/2024

Alvotech to Participate in Jefferies Healthcare Conference in New York, June…

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies Healthcare Conference in New York on June 5-6, 2024. Alvotech will present and host investor and business meetings at the conference.Anil Okay, Chief Business Officer, is scheduled to give a presentation at the conference on June 6, 2024, at 1:00 pm EDT (17:00 GMT). An audio webcast of the...
Nasdaq GlobeNewswire
29/05/2024

BioNTech and CEPI Expand Partnership to Strengthen Africa's mRNA Vaccine…

BioNTech and CEPI aim to enhance local R&D, clinical and commercial-scale manufacturing capacities to develop potential mRNA vaccines in Africa, for AfricaCEPI to fund up to $145 million to support BioNTech in broadening the scope of the manufacturing facility in Kigali, Rwanda, aimed at addressing needs of African countries and in compliance with global standards Partnership intends to contribute to building a sustainable and resilient end-to-end African vaccine ecosystem...
Nasdaq GlobeNewswire
29/05/2024

Zealand Pharma major shareholder announcement: Polar Capital

Company announcement – No. 28 / 2024 Zealand Pharma major shareholder announcement: Polar CapitalCopenhagen, Denmark, 29 May 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 24 May 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:As of 22...
Nasdaq GlobeNewswire
29/05/2024

Veritas Genetics at the forefront of genomic screening with new studies…

In this 57th edition of ESHG, Veritas will showcase its comprehensive portfolio in preventive medicine and will participate with a booth (number 240) where its latest advances and services will be exhibited. In this 57th edition of ESHG, Veritas will showcase its comprehensive portfolio in preventive medicine and will participate with a booth (number 240) where its latest advances and services will be exhibited. Innovative Studies Veritas will present two abstracts at this edition of...
PR Newswire
29/05/2024
Altri  Comunicati